Clin Osteol 2008; 13(2): 65-70

Bone mineral density and selected parameters of bone turnover in patients with systemic lupus erythematosusCase reports

M. ®urek, P. Horák, J. Lukeą, K. Langová, V. ©čudla

Keywords: systémový lupus er

Published: December 11, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
®urek M, Horák P, Lukeą J, Langová K, ©čudla V. Bone mineral density and selected parameters of bone turnover in patients with systemic lupus erythematosus. Osteologický bulletin. 2008;13(2):65-70.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Merrel M, Shulman LE. Determination of prognosis in chronic disease, illustr by systemic lupus eryth-ematosus. J Chronic Dis 1955;1:12-32. Go to original source...
    2. Formiga F, Moga I, Nolla JM, et al. Loss of bone mineral density in premenopauzal women with systemic lupus erythematosus. Ann Rheum Dis 1995;54: 274-276. Go to original source...
    3. Bhattoa HP, Bettembuk P, Balogh A, et al. Bone mineral density in women with systemic lupus erythematosus. Clin Rheumatol 2002;21:135-141. Go to original source...
    4. Sinigaglia L, Varenna M, Binelli L, et al. Determinants of bone mass in s lupus erythematosus: a cross sectional study on premenopauzal women. J Rheu­ matol 1999;26:1280-1284.
    5. Rhew EY, Lee C, Eksarko P, et al. Homocysteine, bone mineral density, and frac­ ture risk over 2 years of followup in women with and withou hematosus. J Rheumatol. 2008;35(2):230-6. Epub 2008 Jan 15.
    6. Kashef S, Saki F, Karamizadeh Z, et. al. Bone mineral density in children wth s temic lupus erythematosus and juvenile rheumatoid arthritis. Ann Saudi Med. 2007;27(6):427-31. Go to original source...
    7. Redlich K, Ziegler S, Kiener HP,et al. Bone mineral density and biochemical pa­ rameters of bone metabolizm in female patients with systemic lupus erythemato­ sus. Ann Rheum Dis. 2000;59:308-10. Go to original source...
    8. Hansen M, Halberg P, Kollerup G,et al. Bone metabolizm in patients with syste­ mic lupus erythematosus. Effect of disease activity and glucocorticoid treatment. Scand J Rheumatol 1998;27:197-206. Go to original source...
    9. Becker A, Fischer R, Schneider M. Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus Z Rheumatol. 2001;60:352-8. Go to original source...
    10. Tan EM, Cohen AS, Fries JF,et al. The 1982 revised criteria for the classific of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. Go to original source...
    11. Kanis JA, Melton LJ 3rd,Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137 -1141. Go to original source...
    12. NE Lane, Q Rehman. Osteoporosis in the rheumatic disease patient. Lupus 2002;11:675-679. Go to original source...
    13. Di Munno O, Mazzantini M, Delle Sedie A, et al. Risk factors for osteopo female patients with systemic lupus erythematosus. Lupus. 2004;13(9):724-30. Go to original source...
    14. Norimatsu H, Mori S, Kawanishi J, Kaji Y, Li J. Immobilization as the pathoge­ nesis of osteop Suppl 3:S57-62.
    15. Caraballo PJ, Heit JA, Atkinson EJ et al. Long-term use of oral anticoagula the risk of fracture. Arch Intern Med 1999;159:1750-1756. Go to original source...
    16. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996;65:171-4. Go to original source...
    17. Bhattoa HP, Kiss E, Bettembuk P, Balogh A Bone mineral denzity, biochemical markers of bone turnover, and hormonal status in men with SLE. Rheumatol. Intenationa 2001;21:97-102. Go to original source...
    18. Ramsey-Goldman R, Dunn JE, Huang CF,et. al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999;42:882-90. Go to original source...
    19. Růľičková O, Bayer M, Pavelka K, Palička V. Společnost pro metabolickáonemocnění skeletu ČLS JEP, Česká revmatologická společnost ČLS JEP. Doporu­ čení pro prevenci a léčbu glukokortikoidy indukované osteoporózy u pacientů s revmatickým onemocněním (Společné stanovisko České revmatologické společ­ nosti a Společnosti pro metabolická onemocnění skeletu) Čes. Revmatol 2004;12: 163-74.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.